UMB Bank n.a. Sells 3,915 Shares of Merck & Co., Inc. (NYSE:MRK)

UMB Bank n.a. trimmed its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 255,979 shares of the company’s stock after selling 3,915 shares during the quarter. UMB Bank n.a.’s holdings in Merck & Co., Inc. were worth $27,907,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MRK. Cantor Fitzgerald Investment Advisor L.P lifted its stake in shares of Merck & Co., Inc. by 94.2% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 349,588 shares of the company’s stock valued at $28,683,000 after purchasing an additional 169,536 shares during the period. BCK Partners Inc. acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at $2,423,000. NewEdge Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 6.3% in the 1st quarter. NewEdge Advisors LLC now owns 159,225 shares of the company’s stock valued at $13,064,000 after purchasing an additional 9,376 shares during the period. First Western Trust Bank acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at $1,078,000. Finally, Equitable Holdings Inc. lifted its stake in shares of Merck & Co., Inc. by 12.9% in the 1st quarter. Equitable Holdings Inc. now owns 36,124 shares of the company’s stock valued at $2,964,000 after purchasing an additional 4,131 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Merck & Co., Inc. Stock Performance

MRK opened at $130.35 on Wednesday. The business’s 50-day moving average price is $125.45 and its two-hundred day moving average price is $113.20. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $133.10. The company has a market capitalization of $330.13 billion, a price-to-earnings ratio of 931.07, a P/E/G ratio of 0.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. The firm had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $1.62 EPS. Equities analysts expect that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on MRK shares. Barclays increased their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. Finally, UBS Group raised their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.71.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.